Mekinist is a prescription medicine used to treat the symptoms of Melanoma, Non-Small Cell Lung Cancer, and Thyroid Cancer. Mekinist may be used alone or with other medications. MEKINIST (trametinib) tablets can be imported for personal use under "patient name basis" treatment in India. For this applicant is required to make an request application with required document. IPN, New Delhi will do the necessary process to obtain permission from Drugs Controller General (India) to import.
Therapeutic indications and Usage
MEKINIST is a kinase inhibitor indicated as a single agent and in combination with dabrafenib for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations as detected by an FDA-approved test. The use in combination is based on the demonstration of durable response rate. Improvement in disease-related symptoms or overall survival has not been demonstrated for MEKINIST in combination with dabrafenib. Active ingredient: trametinib Inactive ingredients: Tablet Core: colloidal silicon dioxide, croscarmellose sodium, hypromellose, magnesium stearate (vegetable source), mannitol, microcrystalline cellulose, sodium lauryl sulfate.
Generic Name: trametinib tablets
Brand Name: Mekinist
Drug Class: Antineoplastics MEK Inhibitors
Company Name: Novartis Pharmaceuticals Corporation.
Source Details: Patient Information
Patient Name Basis Treatment IPN, New Delhi can facilitate patient to import of "MEKINIST (trametinib) tablets" in quantities for personal use. For this applicant is required to make an application in Form 12A, along with the prescription of the Registered Medical Practitioner (RMP).
Health Professional In India
If you have any question, please email IPN Support Team or Call Indian Pharma Network for MEKINIST (trametinib) tablets price list or cost in India. on
Mr. Tarun:- +91 9891 296 838
Mr. Neeraj:- +91 9811 747 774
We are the facilitator, group of highly qualified healthcare professionals, provide solutions on how to get access of anti cancer medicines not available in India. On the basis of permission in Form 12B (Import permit) from From Ministry of Health, Government of India, IPN, New Delhi procure drugs on behalf of patient.
MEKINIST is a prescription medicine used by itself or in combination with dabrafenib to treat people with a type of skin cancer called melanoma: • that has spread to other parts of the body or cannot be removed by surgery, and • that has a certain type of abnormal “BRAF” gene. MEKINIST should not be used alone to treat people who already have received a BRAF inhibitor for treatment of their melanoma. Mekinist belongs to a class of drugs called Antineoplastics, MEK Inhibitors.
Source content : www.accessdata.fda.gov
IPN, New Delhi can facilitate patient to import of "MEKINIST (trametinib) tablets" in quantities for personal use. Expertise in Specialty Pharmaceutical distribution having its PAN India presence in Delhi, Mumbai, Kolkata, Chennai, Bangalore, Hyderabad, Ahmedabad, Pune, Visakhapatnam, Surat, Jaipur, Coimbatore, Kanpur, Nagpur, Raipur, Kochi, Kozhikode, Nashik, Salem, Thiruvananthapuram, Madurai, Jodhpur, Noida, Gurgaon, Punjab, Chandigarh, Bhubaneswar, Arunachal Pradesh, Assam, Manipur, Meghalaya, Mizoram, Nagaland, Tripura and Sikkim, India. with over 20 years of domain experience.
For procurement cost of MEKINIST (trametinib) tablets in India, Please call at M: +91 9811747774 (Mr. Tarun) / 9891296838 (Mr. Neeraj) or Email Us to know more details about the MEKINIST (trametinib) tablets medicine cost price in India.
The order for MEKINIST (trametinib) tablets will be confirmed only after
1. submitting Form 12A, along with the prescription of the Registered Medical Practitioner (RMP).
2. Permission from obtained from the office of the Drugs Controller General (India).
3. Availability of MEKINIST (trametinib) tablets from authorised distributor.
Trametinib is a cancer drug. It is a MEK inhibitor drug with anti-cancer activity. It inhibits MEK1 and MEK2. Trametinib had good results for metastatic melanoma carrying the BRAF V600E mutation in a phase III clinical trial. In this mutation, the amino acid valine (V) at position 600 within the BRAF protein has become replaced by glutamic acid (E) making the mutant BRAF protein constitutively active. In May 2013, trametinib was approved as a single-agent by the Food and Drug Administration for the treatment of patients with V600E mutated metastatic melanoma. Clinical trial data demonstrated that resistance to single-agent trametinib often occurs within 6 to 7 months. To overcome this, trametinib was combined with the BRAF inhibitor dabrafenib. As a result of this research, on January 8, 2014, the FDA approved the combination of dabrafenib and trametinib for the treatment of patients with BRAF V600E/K-mutant metastatic melanoma. On May 1, 2018, the FDA approved the combination dabrafenib/trametinib as an adjuvant treatment for BRAF V600E-mutated, stage III melanoma after surgical resection based on the results of the COMBI-AD phase 3 study, making it the first oral chemotherapy regimen that prevents cancer relapse for node positive, BRAF-mutated melanoma. In a person with a sequence variant in the ARAF gene, trametinib helped the lymphatic system to remodel toward a healthier state, reducing lymphatic edema. This benefit would not occur in most people because it is specific to genomes similar to the reported one, but it is potentially lifesaving for the few people with such genomes. This case provides an example of what precision medicine can accomplish.
MEKINIST (trametinib) tablets, for oral use Initial U.S. Approval: 2013
0.5-mg Tablets: Yellow, modified oval, biconvex, film-coated tablets with ‘GS’ debossed on one face and ‘TFC’ on the opposing face. 1-mg Tablets: White, round, biconvex, film-coated tablets with ‘GS’ debossed on one face and ‘LHE’ on the opposing face. 2-mg Tablets: Pink, round, biconvex, film-coated tablets with ‘GS’ debossed on one face and ‘HMJ’ on the opposing face.
For MEKINIST (trametinib) tabletsIndications And Usage, Dosage And Administration, Dosage Forms And Strengths and Drug Interactions For More Details
Dabrafenib in Combination With Trametinib for Unresectable or Metastatic Solid Tumors With BRAF V600E Mutation For More Details
Trametinib With or Without Dabrafenib in Pediatric BRAF V600–Mutant Low-Grade Glioma For More Details
FDA Grants Accelerated Approval to Dabrafenib Plus Trametinib for BRAF V600E+ Tumor-Agnostic Indication For More Details
Step 1. Send a request for your medicine online:-Applicant is required to make an application in Form 12A, along with the prescription of the Registered Medical Practitioner (RMP).
Step 2. Verification of documents:-We verify your a prescription and necessary documents to import drugs in quantities for personal use.
Step 3. Permission to Import:-After getting approval of Drugs Controller General (India), we start the process to import of drugs as mentioned in prescription for personal use.
Step 4. We source your medicine:-Our expert sourcing team work with our global network of suppliers to find you the best price. Once we have found you the lowest possible cost for your medicine, we will present you with a final offer for your approval.
Step 5. Delivery of medicine:-After you have accepted our offer, our experienced logistics team will arrange all the shipping and transportation of your medicine.
Doctor’s Prescription –
We would require prescription from Registered Medical Practitioner (RMP) stating product name, dosage, duration of treatment and diagnosis.
Patient’s Medical history –
We would require all test reports and medical reports of the patient for last 3 months.
Patient’s Identity card –
We will require scan copy of patient’s identity card and proof of residence to initiate documentation process.
Almost all countries across the world have provisions for granting access to drugs prior to marketing approval for personal use for patients who have exhausted all other treatment options available in their country. Indian Pharma Network, New Delhi can help patients in accessing/importing Ant-cancer medicines, unapproved in their home country against a legitimate prescription and in conformity with all local laws and regulations of their home country.
Send your query to find out -
MEKINIST (trametinib) tablets price in South East Asia – China (Beijing, Chongqing, Shanghai, Tianjin and Shenzhen), Cambodia, Indonesia, Malaysia, the Philippines, Singapore, Thailand, Vietnam, Hong Kong.
MEKINIST (trametinib) tablets price in United Arab Emirates – Iraq, Iran, Saudi Arabia, Jordan.
MEKINIST (trametinib) tablets price in North America – Mexico.
MEKINIST (trametinib) tablets price in South America – Argentina, Brazil, Chile, Colombia, Peru, Venezuela.
MEKINIST (trametinib) tablets price in Europe – Romania, Switzerland, Georgia, Turkey, Italy, UK, Ukraine, Azerbaijan, Latvia, Poland, Slovakia.
MEKINIST (trametinib) tablets price in Russia CIS – Armenia, Kazakhstan, Moldova, Tajikistan, Turkmenistan, Uzbekistan, Mongolia.
MEKINIST (trametinib) tablets price in African Countries – Algeria, Mauritius, Uganda, Zimbabwe.
MEKINIST (trametinib) tablets price in Australia and New Zealand.
Your order will be shipped to you by our partner couriers, such as DHL, UPS and specialised cold chain couriers. If you would like your order to be shipped by a specific courier, please inform us when you place the order. Our standard delivery time varies from 5 to 10 working days. The shipping cost depends on the medicine and the destination country. After making an enquiry, you will receive a detailed quote that includes the shipping costs.